Pages that link to "Q28294644"
Jump to navigation
Jump to search
The following pages link to Serotonin reuptake inhibitor withdrawal (Q28294644):
Displaying 50 items.
- Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved (Q21129279) (← links)
- Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria (Q24541080) (← links)
- Dapoxetine: a new option in the medical management of premature ejaculation (Q24601186) (← links)
- Antidepressant discontinuation syndromes (Q28188383) (← links)
- Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone (Q28201146) (← links)
- Moclobemide discontinuation syndrome predominantly presenting with influenza-like symptoms (Q28202313) (← links)
- Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. (Q30249670) (← links)
- Neuroleptic discontinuation syndromes (Q33538378) (← links)
- The role of fluoxetine in the treatment of premenstrual dysphoric disorder (Q33654948) (← links)
- The place for the tricyclic antidepressants in the treatment of depression (Q33708766) (← links)
- Pharmacological stress diathesis syndromes (Q33747174) (← links)
- Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? (Q33940520) (← links)
- Neurological bases for balance-anxiety links (Q33949526) (← links)
- The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders (Q33952498) (← links)
- Shock‐Like Sensations During Venlafaxine Withdrawal (Q33965966) (← links)
- Tolerability and safety of fluvoxamine and other antidepressants (Q33995120) (← links)
- The SSRI discontinuation syndrome (Q34013432) (← links)
- Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders (Q34086053) (← links)
- Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up (Q34113960) (← links)
- Antidepressants, old and new. A review of their adverse effects and toxicity in overdose (Q34114440) (← links)
- Neurotropic and psychotropic drugs in dermatology (Q34129811) (← links)
- Efficacy and Safety of Dapoxetine for the Treatment of Premature Ejaculation: Integrated Analysis of Results from Five Phase 3 Trials (Q34148678) (← links)
- SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents (Q34162104) (← links)
- Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression (Q34182008) (← links)
- A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD) (Q34183517) (← links)
- Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature (Q34201451) (← links)
- Oral Agents for the Treatment of Premature Ejaculation: Review of Efficacy and Safety in the Context of the Recent International Society for Sexual Medicine Criteria for Lifelong Premature Ejaculation (Q34201854) (← links)
- The evaluation and treatment of depression in primary care (Q34250242) (← links)
- Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo (Q34378212) (← links)
- Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine (Q34449097) (← links)
- Withdrawal Reactions Associated with Venlafaxine (Q34468185) (← links)
- Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study (Q34536631) (← links)
- A survey of prescribing practices in the treatment of depression. (Q34537337) (← links)
- Dapoxetine for premature ejaculation (Q34620485) (← links)
- Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial (Q34748493) (← links)
- Drug induced nightmares--an etiology based review (Q35047558) (← links)
- Adverse drug reactions associated with antipsychotics, antidepressants, and mood stabilizers (Q35113921) (← links)
- Major depressive disorder in the general hospital: adaptation of clinical practice guidelines (Q35127999) (← links)
- SSRI discontinuation syndrome. Awareness as an approach to prevention (Q35202596) (← links)
- Are all antidepressants alike? (Q35236137) (← links)
- Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression (Q35587678) (← links)
- Death and dependence: current controversies over the selective serotonin reuptake inhibitors (Q35660695) (← links)
- A Case Report of Onset of Tinnitus Following Discontinuation of Antidepressant and a Review of the Literature (Q35977716) (← links)
- Antidepressant-induced manic conversion: a developmentally informed synthesis of the literature (Q36248038) (← links)
- Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal? (Q37125481) (← links)
- Treating depressed children with antidepressants: more harm than benefit? (Q37357157) (← links)
- Efficacy of dapoxetine in the treatment of premature ejaculation (Q37463029) (← links)
- Safety of selective serotonin reuptake inhibitors in pregnancy (Q37500500) (← links)
- Sensory disturbances associated with serotonin reuptake inhibitors: brief review. (Q37725845) (← links)
- Controversies Surrounding Pediatric Psychopharmacology (Q37898791) (← links)